Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Oncolytics Biotech ( (TSE:ONC) ) just unveiled an announcement.
Oncolytics Biotech has announced key advancements in its pipeline for 2025, highlighting significant progress with its immunotherapy agent, pelareorep, in treating pancreatic and anal cancers, in addition to metastatic breast cancer. Recent regulatory and clinical developments, including safety clearance from Germany’s Paul-Ehrlich-Institute to advance a pancreatic cancer study, and promising data presented at the ASCO GI 2025 Symposium, underscore pelareorep’s potential in diverse cancer treatments. These milestones are expected to de-risk pelareorep’s development, potentially paving the way for larger clinical trials and advancing Oncolytics’ position in the oncology space, providing new treatment options for patients and creating value for shareholders.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is active in the field of immunotherapy for oncology, specifically targeting hard-to-treat cancers such as metastatic breast cancer and gastrointestinal cancers, including pancreatic and anal cancers.
YTD Price Performance: -17.44%
Average Trading Volume: 1,238,109
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $60.25M
For detailed information about ONC stock, go to TipRanks’ Stock Analysis page.
